Legend Biotech Q3 2026: EPS Far Exceeds Expectations on Cost Discipline

Legend Biotech reported adjusted EPS of $0.14 for the third quarter of 2026 against a consensus estimate of just $0.01, far exceeding expectations. Revenue came in at $359.5 million, essentially in line with the $359.9 million estimate, rising 32% year over year. The cost structure underneath the top line drove the quarter.

The company swung to an operating profit of $46.8 million from an operating loss of $43.3 million in the same quarter a year ago. R&D spending fell as cilta-cel clinical trials moved past their heaviest dosing phases, and administrative expenses dropped, partly because a reversal of share-based compensation tied to forfeited equity awards produced a credit in that line item.

CARVYKTI net trade sales totaled $710 million globally in the quarter, up 36% year over year. U.S. sales grew 19% while sales outside the United States expanded 86%, reflecting the broader rollout of the therapy across 373 treatment sites in 20 markets. Legend records its 50% share of those sales as collaboration revenue, which came to $353.2 million.

The commercial backdrop is becoming more favorable. Updated NCCN guidelines now recommend referring all multiple myeloma patients to a CAR-T capable center at first relapse and explicitly prefer CAR-T over T-cell engagers when both BCMA-directed options are available. That positions CARVYKTI for share gains in the second and third line setting, which management identified as a meaningful growth opportunity.

On the pipeline front, the FDA cleared an investigational new drug application for LB2501, a CD19/CD20 dual-targeting in vivo CAR-T candidate aimed at relapsed or refractory B-cell malignancies including B-cell non-Hodgkin lymphoma, with a U.S. Phase I/II trial planned. Five-year follow-up data from CARTITUDE-2 Cohort A showed that half of the 20 patients in that study remained alive and progression-free after a single infusion, adding to the long-term evidence base for cilta-cel in earlier treatment lines.

One item to watch is operating cash flow, which came in at negative $35.9 million despite the reported operating profit, a divergence investors will want to monitor as Legend pursues what management described as sustained profitability through 2026 and beyond. No numeric guidance was provided for future periods.